Cowen & Co. Maintains Their Buy Rating on Galapagos (GLPG)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Galapagos (GLPG). The company’s shares closed last Monday at $270.48, close to its 52-week high of $270.88.

According to, Nadeau is a 5-star analyst with an average return of 8.7% and a 52.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Hold analyst consensus rating for Galapagos with a $192.60 average price target.

See today’s analyst top recommended stocks >>

Galapagos’ market cap is currently $16.11B and has a P/E ratio of 49.12. The company has a Price to Book ratio of 5.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts